Extracorporeal Membrane Oxygenation Cannula

Global Extracorporeal Membrane Oxygenation Cannula Market to Reach US$39.2 Million by 2030

The global market for Extracorporeal Membrane Oxygenation Cannula estimated at US$32.7 Million in the year 2024, is expected to reach US$39.2 Million by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Veno-Arterial, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$19.5 Million by the end of the analysis period. Growth in the Veno-Venous segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.9 Million While China is Forecast to Grow at 5.6% CAGR

The Extracorporeal Membrane Oxygenation Cannula market in the U.S. is estimated at US$8.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.6 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Extracorporeal Membrane Oxygenation (ECMO) Cannula Market - Key Trends & Drivers Summarized

What Are ECMO Cannulas and Why Are They Critical in Life Support?

Extracorporeal Membrane Oxygenation (ECMO) cannulas are specialized medical devices used in ECMO therapy, a form of advanced life support for patients experiencing severe cardiac and respiratory failure. These cannulas serve as the primary conduit for blood circulation outside the body, allowing for oxygenation and carbon dioxide removal in cases where the heart and lungs cannot function adequately. ECMO therapy is widely utilized in critical care, particularly in cases of acute respiratory distress syndrome (ARDS), cardiogenic shock, and post-cardiac surgery recovery. The increasing incidence of respiratory illnesses, cardiac disorders, and pandemic-related complications, such as those seen in COVID-19, has heightened the demand for ECMO cannulas in intensive care units (ICUs) worldwide.

The design and functionality of ECMO cannulas play a crucial role in patient outcomes. These cannulas are engineered for optimal blood flow, reduced hemolysis, and minimized trauma to the vascular system. Their configuration varies based on the type of ECMO therapy employed—venovenous (VV) ECMO for respiratory support and venoarterial (VA) ECMO for both cardiac and pulmonary assistance. The evolution of ECMO cannulas has led to improvements in biocompatibility, durability, and ease of insertion, addressing challenges related to clot formation, infection risks, and patient comfort.

How Are Innovations in ECMO Cannula Design Improving Patient Outcomes?

Technological advancements in ECMO cannula design have significantly improved patient safety, efficiency, and ease of use. One of the most notable developments is the introduction of heparin-coated and antimicrobial cannulas, which reduce the risk of clotting and infection—two major complications associated with prolonged ECMO therapy. Additionally, the use of flexible, wire-reinforced cannulas has enhanced their durability and minimized vessel trauma during insertion and prolonged use.

Another key innovation is the incorporation of percutaneous insertion techniques, which allow for a less invasive and quicker cannulation process, reducing the need for open surgery. Furthermore, advancements in sensor-integrated cannulas are emerging, enabling real-time monitoring of flow dynamics and oxygenation levels, which helps clinicians make precise adjustments and improve overall ECMO management. These developments align with the growing emphasis on reducing ECMO-related complications while enhancing the effectiveness of extracorporeal life support in critically ill patients.

What Factors Are Fueling the Growth of the ECMO Cannula Market?

The increasing prevalence of cardiovascular and respiratory disorders, coupled with rising ICU admissions for critical illnesses, is driving demand for ECMO cannulas. Conditions such as heart failure, sepsis, and chronic obstructive pulmonary disease (COPD) have led to a higher reliance on ECMO therapy, necessitating advancements in cannula technology. The COVID-19 pandemic also underscored the importance of ECMO in managing severe respiratory failure, prompting investments in ECMO infrastructure and equipment.

The growth in the ECMO cannula market is driven by several factors, including the rising incidence of acute respiratory conditions, increasing adoption of ECMO therapy in critical care, and continuous technological advancements in cannula materials and design. Expanding healthcare infrastructure in emerging markets is further fueling demand, as more hospitals and specialized cardiac centers adopt ECMO as a standard life-support measure. Moreover, ongoing research into bioengineered cannulas and integrated monitoring systems is expected to enhance ECMO efficacy, further propelling market expansion. As the need for life-saving extracorporeal therapies continues to rise, the ECMO cannula market is poised for sustained growth, driven by innovation, clinical advancements, and the expanding role of ECMO in critical care management.

SCOPE OF STUDY:

The report analyzes the Extracorporeal Membrane Oxygenation Cannula market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Veno-Arterial, Veno-Venous, Arterio-Venous); Patient (Neonates, Pediatric, Adult); Application (Respiratory Application, Cardiac Application, Ecpr Application); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Abiomed, Inc.
• Andocor
• Biometrix
• Changzhou KangXin Medical Instruments Co., Ltd.
• Edwards Lifesciences Corporation
• Eurosets S.r.l.
• Free Life Medical GmbH
• Fresenius Medical Care AG
• Getinge AB
• LivaNova PLC
• Maquet (a Getinge Group Company)
• MC3 Cardiopulmonary
• Medtronic
• MicroPort Scientific Corporation
• Nipro Corporation
• Novalung GmbH (a Fresenius Medical Care Company)
• Sorin Group (now part of LivaNova)
• Terumo Corporation
• Xenios AG (a Fresenius Medical Care Company)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.